TeGenero

TeGenero was a biotechnology company in Würzburg. It had 15 employees and was a public company since April 2002. The TeGenero GmbH was founded in 2000 as a spin -off of the Medical Faculty of Würzburg University, she received 14 million euros in venture capital.

The first product of TeGenero was the antibody TGN1412, which to humans in the six subjects triggered life-threatening side effects in the first clinical trial in March 2006.

In July 2006 TeGenero went bankrupt because since the incident no further funding more could be raised, which would be necessary for the continuation. The remains were bought by a Russian investor who is carrying on the business as Theramab GmbH. CEO is Sergei Chuvpilo.